Lumirelax 10%
Lumirelax 10% Uses, Dosage, Side Effects, Food Interaction and all others data.
Lumirelax 10% is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Lumirelax 10%'s exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.
The mechanism of action of methocarbamol in humans has not been established, but may be due to general central nervous system (CNS) depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
Methacarbamol is a skeletal muscle relaxant with an unknown mechanism of action. Methacarbamol has been shown to block spinal polysynaptic reflexes, decrease nerve transmission in spinal and supraspinal polysynaptic pathways, and prolong the refractory period of muscle cells. Lumirelax 10% does not act as a local anesthetic upon injection. In animal studies, methocarbamol also prevents convulsions after electric shock.
Trade Name | Lumirelax 10% |
Availability | Prescription only |
Generic | Methocarbamol |
Methocarbamol Other Names | Methocarbamol, Méthocarbamol, Methocarbamolum, Metocarbamol, Metocarbamolo |
Related Drugs | cyclobenzaprine, tizanidine, diazepam, Flexeril, Valium, Robaxin, Soma, chlorpromazine, Thorazine, Robaxin-750 |
Type | |
Formula | C11H15NO5 |
Weight | Average: 241.2405 Monoisotopic: 241.095022595 |
Protein binding | Methocarbamol is 46-50% protein bound in healthy patients and 47.3-48.9% protein bound in hemodialysis patients. |
Groups | Approved, Vet approved |
Therapeutic Class | Centrally acting Skeletal Muscle Relaxants |
Manufacturer | |
Available Country | France |
Last Updated: | September 19, 2023 at 7:00 am |
![Lumirelax 10% Lumirelax 10%](https://www.medicinesfaq.com/media/png/lumirelax-10.png)
Uses
Lumirelax 10% is used for an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of methocarbamol has not been clearly identified, but may be related to its sedative properties. Lumirelax 10% does not directly relax tense skeletal muscles in man
Lumirelax 10% is also used to associated treatment for these conditions: Arthritis, Discomfort, Gouty Arthritis, Muscle Spasms, Pain, Rheumatism, Soreness, Muscle, Tetanus
How Lumirelax 10% works
The mechanism of action of methocarbamol is thought to be dependant on its central nervous system depressant activity. This action may be mediated through blocking spinal polysynaptic reflexes, decreasing nerve transmission in spinal and supraspinal polysynaptic pathways, and prolonging the refractory period of muscle cells. Lumirelax 10% has been found to have no effect on contraction of muscle fibres, motor end plates, or nerve fibres.
Dosage
Lumirelax 10% dosage
Lumirelax 10% 500 mg:
- Initial dosage: 1500 mg (3 tablets) q.i.d.
- Maintenance dosage: 2 tablets q.i.d.
Lumirelax 10% 750 mg:
- Initial dosage: 1500 mg (2 tablets) q.i.d.
- Maintenance dosage: 1 tablet q.4h. or 2 tablets t.i.d.
Six grams a day are recommended for the first 48 to 72 hours of treatment. (For severe conditions 8 grams a day may be administered). Thereafter, the dosage can usually be reduced to approximately 4 grams a day.
Side Effects
Body as a whole: Anaphylactic reaction, angioneurotic edema, fever, headache
Cardiovascular system: Bradycardia, flushing, hypotension, syncope, thrombophlebitis
Digestive system: Dyspepsia, jaundice (including cholestatic jaundice), nausea and vomiting
Hemic and lymphatic system: Leukopenia
Immune system: Hypersensitivity reactions
Nervous system: Amnesia, confusion, diplopia, dizziness or lightheadedness, drowsiness, insomnia, mild muscular incoordination, nystagmus, sedation, seizures (including grand mal), vertigo
Skin and special senses: Blurred vision, conjunctivitis, nasal congestion, metallic taste, pruritus, rash, urticaria
Toxicity
Overdose of methocarbamol may be associated with alcohol and other central nervous system depressants. Patients may experience nausea, drowsiness, blurred vision, hypotension, seizures, and coma. Treatment of overdose is generally through airway maintenance, monitoring urinary output, vital signs, and giving fluid intravenously if necessary.
The oral LD50 in rats is 3576.2mg/kg.
The FDA has classified methocarbamol as pregnancy category C. Animal and human studies have not been performed to determine the risks to a fetus, however fetal and congenital abnormalities have been reported. Lumirelax 10% is excreted in the milk of dogs, however it is unknown if this is also the case for humans. Caution should be exercised when taking methocarbamol while breastfeeding.
Studies to assess the carcinogenicity, mutagenicity, or effects on fertility of methocarbamol have not been performed.
Precaution
Patients should be cautioned that methocarbamol may cause drowsiness or dizziness, which may impair their ability to operate motor vehicles or machinery. Because methocarbamol may possess a general CNS-depressant effect, patients should be cautioned about combined effects with alcohol and other CNS depressants.
Since methocarbamol may possess a general CNS depressant effect, patients receiving methocarbamol should be cautioned about combined effects with alcohol and other CNS depressants. Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards
Interaction
Lumirelax 10% may inhibit the effect of pyridostigmine bromide. Therefore, methocarbamol should be used with caution in patients with myasthenia gravis receiving anticholinesterase agents.
Food Interaction
- Avoid alcohol.
- Take with or without food. The absorption is unaffected by food.
[Moderate] GENERALLY AVOID: Alcohol may potentiate some of the pharmacologic effects of CNS-active agents.
Use in combination may result in additive central nervous system depression and
MANAGEMENT: Patients receiving CNS-active agents should be warned of this interaction and advised to avoid or limit consumption of alcohol.
Ambulatory patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
Lumirelax 10% Drug Interaction
Major: acetaminophen / hydrocodoneModerate: zolpidem, diphenhydramine, duloxetine, escitalopram, pregabalin, metoprolol, alprazolam, cetirizineUnknown: amphetamine / dextroamphetamine, aspirin, celecoxib, omega-3 polyunsaturated fatty acids, cyclobenzaprine, albuterol, levothyroxine, acetaminophen, cyanocobalamin, ascorbic acid, cholecalciferol
Lumirelax 10% Disease Interaction
Volume of Distribution
Volume of distribution data in humans is scarce. In horses, the volume of distribution is 515-942mL/kg at steady state or 724-1130mL/kg.
Elimination Route
The time to maximum concentration is 1.1 hours for both healthy patients and those on hemodialysis. The maximum plasma concentration is 21.3mg/L for healthy patients and 28.7mg/L in hemodialysis patients. The area under the curve for healthy patients is 52.5mg/L*hr and 87.1mg/L*hr in hemodialysis patients. AUC% based on terminal elimination half life is 2% for healthy patients and 4% for hemodialysis patients.
Older studies report maximum plasma concentrations in 0.5 hours.
Half Life
The elimination half life is 1.14 hours in healthy subjects and 1.24 hours in subjects with renal insufficiency. Older studies report half lives of 1.6-2.15 hours.
Clearance
0.2-0.8L/h/kg.
Elimination Route
In humans the majority of the dose is eliminated in the urine. In dogs, 88.85% of the dose is eliminated in urine and 2.14% in the feces. In rats, 84.5-92.5% of the dose is eliminated in the urine and 0-13.3% is eliminated in the feces.
Pregnancy & Breastfeeding use
Pregnancy Category C. Animal reproduction studies have not been conducted with methocarbamol. It is also not known whether methocarbamol can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. methocarbamol should be given to a pregnant woman only if clearly needed.
Safe use of methocarbamol has not been established with regard to possible adverse effects upon fetal development. There have been reports of fetal and congenital abnormalities following in utero exposure to methocarbamol. Therefore, methocarbamol should not be used in women who are or may become pregnant and particularly during early pregnancy unless in the judgment of the physician the potential benefits outweigh the possible hazards
Nursing Mothers: Lumirelax 10% and/or its metabolites are excreted in the milk of dogs; however, it is not known whether methocarbamol or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Lumirelax 10% is administered to a nursing woman.
Contraindication
Lumirelax 10% is contraindicated in patients hypersensitive to methocarbamol or to any of the tablet components.
Special Warning
Pediatric Use: Safety and effectiveness of Lumirelax 10% in pediatric patients below the age of 16 have not been established.
Acute Overdose
Limited information is available on the acute toxicity of methocarbamol. Overdose of methocarbamol is frequently in conjunction with alcohol or other CNS depressants and includes the following symptoms: nausea, drowsiness, blurred vision, hypotension, seizures, and coma. In post-marketing experience, deaths have been reported with an overdose of methocarbamol alone or in the presence of other CNS depressants, alcohol or psychotropic drugs.
Management of overdose includes symptomatic and supportive treatment. Supportive measures include maintenance of an adequate airway, monitoring urinary output and vital signs, and administration of intravenous fluids if necessary. The usefulness of hemodialysis in managing overdose is unknown.
Storage Condition
Store at controlled room temperature, between 20°C and 25°C
Innovators Monograph
You find simplified version here Lumirelax 10%
Lumirelax 10% contains Methocarbamol see full prescribing information from innovator Lumirelax 10% Monograph, Lumirelax 10% MSDS, Lumirelax 10% FDA label